Key facts
- It has raised $15.1M across 1 recorded rounds; the latest was Seed Round ($1.6M) in Mar 2021.
- Notable investors include First Avenue Ventures, Timberline Holdings, Biostack Ventures, Sororibus Capital, University of Alabama at Birmingham.
- ResBiotic has filed 1 Form D with the SEC, most recently Mar 2021 ($1.6M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for ResBiotic
Funding rounds
1 roundsAbout ResBiotic
Developer of probiotic therapies designed to restore a healthy lung microbiome. The company specializes in developing an anti-inflammatory probiotic product that targets the gut-lung axis to reduce neutrophilic inflammation, enabling patients to cure their suffering from respiratory illnesses.
- Sector
- Healthcare
- HQ
- Birmingham, AL, United States
- Founded
- 2020
- Employees
- 15
- Website
- resbiotic.com/
- Ownership
- Privately Held (backing)
ResBiotic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ResBiotic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ResBiotic in its N-PORT filings yet. We sweep new filings monthly.